NanoLogix Inc. to Present at The American Society for Microbiology (ASM) General Meeting in Boston; Announces Product Line and P
29 May 2008 - 1:00AM
PR Newswire (US)
HUBBARD, Ohio, May 28 /PRNewswire-FirstCall/ -- NanoLogix, Inc.
(Pink Sheets: NNLX) a nano-biotechnology company is pleased to
provide the following updates: NanoLogix personnel will showcase
company technology at booth 1304 at the ASM General Meeting and
Exhibition in Boston, June 1-5 2008. The ASM meeting is the world's
premier event for microbiology development. Representing NanoLogix
will be Dr. Sergey Gazenko and CEO Bret Barnhizer. Exhibition
information can be found at http://gm.asm.org/ At the ASM meeting
NanoLogix will unveil ten products for use with their BNC and BNP
technology for fast microorganism detection. This step is a
milestone in company development. Director and company founder Dr.
Robert A. Ollar, M.Sc., Ph.D. stated: "The sale of products
developed by NanoLogix scientific staff marks an important stage in
the evolution of the company. The firm is now putting its
technologies into actual product configurations, and offering them
for sale in the international market place where they will be
utilized by the Global Scientific Community." The company is also
planning a new research and development facility in northeast Ohio.
This facility will enable expanded R&D work on both Biohydrogen
reactor development and BioNanoChannel (BNC) and BioNanoPore (BNP)
technologies. Hilda E. Diaz has joined NanoLogix in Cincinnati as
assistant to Dr. Sergey Gazenko. Ms. Diaz holds an MS in
Microbiology from Xavier University in Colombia, a BS in
Bacteriology from Catholic University, and a BA in Business
Administration. Ms. Diaz has extensive research and work experience
in the field of microbiology. She was Professor in general
microbiology, food microbiology and biotechnology at Catholic
University in Colombia, and has extensive industrial experience in
bacteriological testing. The company is pleased to have Ms. Diaz
contributing to its efforts to further both Biohydrogen and
BioNanoChannel technologies. About NanoLogix, Inc. NanoLogix is a
leading innovator in the research, development, and
commercialization of nano-biotechnologies, applications and
processes. The Company has 31 granted Patents and multiple Patents
Pending for bioreactor- based Hydrogen Production, revolutionary
rapid medical testing technologies, and bioremediation. Information
on NanoLogix is available at http://www.nanologixinc.com/. This
press release contains statements, which may constitute "forward-
looking statements" within the meaning of the Securities Act of
1933 and the Securities Exchange Act of 1934, as amended by the
Private Securities Litigation Reform Act of 1995. Those statements
include statements regarding the intent, belief or current
expectations of NanoLogix, Inc., and members of its management as
well as the assumptions on which such statements are based.
Prospective investors are cautioned that any such forward-looking
statements are not guarantees of future performance and involve
risks and uncertainties, and that actual results may differ
materially from those contemplated by such forward-looking
statements. The Company undertakes no obligation to update or
revise forward-looking statements to reflect changed assumptions,
the occurrence of unanticipated events or changes to future
operating results. Contact: Investor Relations Bret Barnhizer, CEO
Telephone: 330-534-0800 E-mail: DATASOURCE: NanoLogix, Inc.
CONTACT: Bret Barnhizer, CEO of NanoLogix, Inc., +1-330-534-0800,
Web site: http://www.nanologixinc.com/ http://gm.asm.org/
Copyright